Achievement of Diabetes-related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)

被引：0
|
作者：
Blonde, Lawrence
Woo, Vincent
Mathieu, Chantal
Yee, Jacqueline
Vijapurkar, Ujjwala
Meininger, Gary
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1093-P
引用
收藏
页码：A284 / A284
页数：1
相关论文
共 50 条
  • [41] Triple-Goal Achievement in Patients with Type 2 Diabetes Mellitus (T2DM) Improves Clinical Outcomes
    Shi, Qian
    Shi, Lizheng
    Fonseca, Vivian
    [J]. DIABETES, 2015, 64 : A236 - A236
  • [42] ASSESSMENT OF THE KEY DRIVERS OF COST-EFFECTIVENESS IN THE ECONOMIC MODELLING OF CANAGLIFLOZIN (CANA) VERSUS GLIMEPIRIDE (GLIM) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK SETTING
    Thompson, G.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Schroeder, M.
    Girod, I
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [43] The improvement of sulforaphane in type 2 diabetes mellitus (T2DM) and related complications: A review
    Wang, Mengjiao
    Chen, Min
    Guo, Rui
    Ding, Yangyang
    Zhang, Haihui
    He, Yuanqing
    [J]. Trends in Food Science and Technology, 2022, 129 : 397 - 407
  • [44] The improvement of sulforaphane in type 2 diabetes mellitus (T2DM) and related complications: A review*
    Wang, Mengjiao
    Chen, Min
    Guo, Rui
    Ding, Yangyang
    Zhang, Haihui
    He, Yuanqing
    [J]. TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2022, 129 : 397 - 407
  • [45] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM
    Schroeder, M.
    Johansen, P.
    Thompson, G.
    Willis, M.
    Neslusan, C.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A344 - A344
  • [46] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [47] HDL EFFLUX CAPACITY, AND PARTICLE REMODELLING IN PATIENTS WITH TYPE 1 DIABETES MELLITUS (T1DM) AND TYPE 2 DIABETES MELLITUS (T2DM)
    Byrne, R.
    Curley, S.
    Ahmed, K.
    Ahmed, M.
    Gibney, J.
    Mcgillicuddy, F.
    [J]. ATHEROSCLEROSIS, 2020, 315 : E65 - E66
  • [48] Improved Treatment Satisfaction in People with Type 1 Diabetes Mellitus (T1DM) Treated with Canagliflozin (CANA)
    Peters, Anne L.
    Rodbard, Helena W.
    Slee, April
    Traina, Shana
    [J]. DIABETES, 2016, 65 : A311 - A311
  • [49] Characteristics of patients with type 2 diabetes mellitus (T2DM) on basal insulin who do not achieve glycaemic goals
    Brunton, S.
    Blonde, L.
    Chava, P.
    Zhou, R.
    Meyers, J.
    Davis, K.
    Dalal, M.
    DiGenio, A.
    [J]. DIABETOLOGIA, 2014, 57 : S54 - S54
  • [50] WEIGHT- AND HEALTH-RELATED QUALITY OF LIFE (WRQOL AND HRQOL) WITH CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS (T2DM) ON BACKGROUND METFORMIN
    Traina, S. B.
    Ho, K. F.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A448 - A448
12345